Comparing two drug combinations for newly diagnosed lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to nearby tissues or other parts of the body (stage III or IV) and is not curable with surgery or radiation alone.
- You have not had any previous treatment for advanced or metastatic lung cancer.
- Your cancer should not have certain gene changes (like EGFR or ALK) that have approved targeted therapies.
- You need to have at least one tumor that can be measured on imaging (like a CT scan or MRI) that is not in the brain.
- You must be in generally good health, with a performance status of 0 or 1, meaning you can still do most daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
This trial tests two investigational drugs combined as a first treatment for people with a type of lung cancer called non-squamous non-small-cell lung cancer that has spread. The aim is to see if the combination is safe and effective.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
Hear when a new Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.